

Special Issue

Long Noncoding RNAs in Drug Metabolism and Human Diseases

Message from the Guest Editor

Drug metabolism is a critical step in pharmacokinetics, and ultimately affects the bioavailability, efficacy, and toxicity of administrated drugs. LncRNAs have exhibited the ability to interact with transcription factors and epigenetic modifiers, exerting regulatory control over genes involved in drug metabolism, including enzymes and transporters. Understanding how lncRNAs affect drug metabolism could be beneficial in predicting drug responses, optimizing drug dosing, and developing personalized therapeutic approaches. LncRNAs have emerged as regulatory factors in the understanding of disease mechanisms, diagnosis, prognosis, and potential therapeutic interventions. LncRNAs also represent a novel therapeutic target for drug discovery, and could be targeted by small molecules or nucleic acid-based therapeutics and thus regulated. Studying lncRNAs in drug metabolism and human disease has provided valuable insights into pharmacokinetics, personalized medication, disease diagnosis, and the mechanisms of diseases. The field holds great promise regarding its ability to enhance drug development and disease control in the future.

Guest Editor

Dr. Liming Chen

Weill Cornell Medicine, Cornell University, New York, NY, USA

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/179625

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).